New combo therapy aims to boost rectal cancer remission
NCT ID NCT07198165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with locally advanced rectal cancer that hasn't spread. It tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation plus chemotherapy and targeted therapy) can lead to a complete disappearance of the cancer. About 104 participants will receive either the standard combination or the standard plus immunotherapy to see which works better and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Which rectal cancer surgery preserves quality of life better? a study investigates
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Can AI learn to grade endoscopy quality from video?
- Can precision protons spare rectal cancer patients from harsh side effects?